Abstracts

1116 – Impact of AIFA Reimbursement on the PrEP-Naive Population Characteristics and Incidence of STIs

Background Pre-exposure prophylaxis (PrEP) is a cornerstone of HIV prevention worldwide. In Italy, a decisive policy shift occurred in May 2023 with the introduction of reimbursement by the Italian Medicines Agency (AIFA). Until then, PrEP was only available out-of-pocket, representing a significant barrier to uptake. Methods Monocentric observational cohort study at IRCCS Policlinico in Milan,…

959 – Laboratory Preevaluation of Triple Rapid Tests for HIV, Syphilis, and Hepatitis B in Uganda

Background Uganda’s drive toward triple elimination of mother-to-child transmission of HIV, syphilis, and hepatitis B demands screening tools that are accurate, rapid, and affordable. Triple rapid diagnostic tests (RDTs) that simultaneously detect HIV antigen/antibody, treponemal antibodies, and hepatitis B surface antigen (HBsAg) provide a consolidated approach suitable for antenatal and routine laboratory screening. Currently, testing…

723 – RCT of 2 Behavioral Counseling Interventions for Smoking Cessation in People With HIV in Botswana

Background People with HIV (PWH) smoke tobacco at higher rates and have lower response rates to smoking cessation interventions than people without HIV. Few counseling resources exist in lower and middle income countries (LMIC), medication assisted treatment is unavailable due to cost and no behavioral interventions are tailored to LMICs. We developed Behavioral Activation/Problem Solving…

742 – COVID-19 Hospitalizations Among Women of Reproductive Age at Risk for and Living With HIV in the US

Background SARS-CoV-2 infection (COVID) is associated with poor reproductive health outcomes, including increased risk of adverse pregnancy events and maternal morbidity. These risks may be exacerbated by HIV infection due to immune dysregulation and higher rates of comorbid conditions. Women with HIV (WWH), particularly those of reproductive age, represent a vulnerable population with overlapping risks…

476 – Pregnenolone Shifts Circulating Monocytes Toward a Regulatory Phenotype in People With HIV

Background A neuroactive steroid (NAS) analog is FDA-approved for postpartum depression and shows efficacy in major depressive disorder (MDD) in people without HIV (PWoH). Pregnenolone, a NAS precursor, exerts anti-inflammatory effects in myeloid cell lines after Toll-like receptor (TLR) stimulation, but its modulation of cytokine production in people with HIV (PWH) is unknown.  Methods Endogenous…

509 – Short Text Messages Improve Antiretroviral Adherence Among People Living With HIV in Georgia

Background Adherence to antiretroviral therapy (ART) is critical for sustained viral suppression among people living with HIV (PLHIV) and to control epidemic. Short message service (SMS) reminders offer a low-cost digital approach to support adherence to ART, but evidence from large-scale national programs remains limited. In Georgia, an automated SMS reminder system was launched in…

597 – Pitavastatin Does Not Improve Hepatic Steatosis in REPRIEVE Mechanistic Substudy Participants

Background Hepatic steatosis (HS), including metabolic dysfunction-associated steatotic liver disease (MASLD), is common among persons with HIV (PWH). We present longitudinal HS and MASLD incidence, prevalence, cardiometabolic characteristics and cardiovascular outcomes among REPRIEVE mechanistic substudy (MS) participants. Methods The REPRIEVE MS was an embedded substudy (N=804) conducted at 31 US sites as part of a…

546 – CD4 and CD4/CD8 as Determinants of Long-Term Risk of Clinical Events After ART Initiation in START

Background START trial randomized ART-naïve individuals with CD4>500 cells/μL to immediate or deferred ART until CD4 declined to 350cells/μL or AIDS developed. From 2015, all participants were recommended to initiate ART, followed through 2021. We examined the predictive value of updated immunological biomarkers on long-term clinical outcomes after ART initiation. Methods Cox models assessed risk…

561 – Rising Dolutegravir Resistance in Tanzania: A Concern for the ART Programme

Background In 2020, Tanzania conducted a facility-based national surveillance of HIV drug resistance among people living with HIV (PLHIV). It was observed that 5.8% of PLHIV experiencing high viremia had integrase strand transfer inhibitors (INSTI) drug resistance mutations (DRMs). Therefore, five years later, we aimed to determine the trends and patterns of acquired drug resistance mutations…

1026 – Exploring 7 vs 21 Days of Doxycycline for Chlamydia trachomatis Lymphogranuloma Venereum Strains

Background According to clinical guidelines, Chlamydia trachomatis lymphogranuloma venereum (LGV), unlike non-LGV cases, should be treated with 21-day doxycycline 100 mg twice daily. However, LGV typing is rarely performed in routine care, due to limited availability and turnaround time, so most cases are empirically managed as non-LGV. The aim of the study was to estimate…